Skip to main content
SpringerLink
Log in

Hedgehog Signaling Pathway Inhibitors for Basal Cell Carcinoma

  • Chapter
  • First Online:
Basal Cell Carcinoma

  • 1022 Accesses

Abstract

As the most common cancer in humans, basal cell carcinomas (BCCs) affect approximately 2.8 million people. Depending on the location, size, tumor subtype, and other factors, treatment may include topical therapy with imiquimod or 5-fluorouracil, cryotherapy, radiation, photodynamic therapy, electrodesiccation and curettage, surgical excision, and Mohs micrographic surgery, the latter of which has the lowest 5-year recurrence rate: between 0.7% and 2.4%. BCC is mainly a localized neoplasm, although less commonly, it can become locally advanced or even metastatic (0.0028–0.55%). Locally advanced BCC (laBCC) and metastatic BCC (mBCC) are both considered advanced BCC

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mohan SV, Chang ALS. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep. 2014;3(1):40–5. https://doi.org/10.1007/s13671-014-0069-y.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Mosterd K, Krekels GAM, Nieman FH, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9(12):1149–56. https://doi.org/10.1016/S1470-2045(08)70260-2.

    Article  PubMed  Google Scholar 

  3. Hill VK, Gartner JJ, Samuels Y, Goldstein AM. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet. 2013;14(1):257–79. https://doi.org/10.1146/annurev-genom-091212-153429.

    Article  CAS  PubMed  Google Scholar 

  4. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol. 2001;137(11):1493–6. http://www.ncbi.nlm.nih.gov/pubmed/11708953. Accessed 24 Dec 2017.

    Article  CAS  PubMed  Google Scholar 

  5. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995;333(15):970–4. https://doi.org/10.1056/NEJM199510123331504.

    Article  CAS  PubMed  Google Scholar 

  6. Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991;24(5 Pt 1):715–9. http://www.ncbi.nlm.nih.gov/pubmed/1869642. Accessed 24 Dec 2017.

    Article  CAS  PubMed  Google Scholar 

  7. Seo S-H, Shim W-H, Shin D-H, Kim Y-S, Sung H-W. Pulmonary metastasis of basal cell carcinoma. Ann Dermatol. 2011;23(2):213–6. https://doi.org/10.5021/ad.2011.23.2.213.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743–54. https://doi.org/10.1038/nrc2503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–28. https://doi.org/10.1016/S1470-2045(15)70100-2.

    Article  CAS  PubMed  Google Scholar 

  10. Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980;287(5785):795–801. http://www.ncbi.nlm.nih.gov/pubmed/6776413. Accessed December 24, 2017.

    Article  PubMed  Google Scholar 

  11. Stone DM, Hynes M, Armanini M, et al. The tumour-suppressor gene patched encodes a candidate receptor for sonic hedgehog. Nature. 1996;384(6605):129–34. https://doi.org/10.1038/384129a0.

    Article  CAS  PubMed  Google Scholar 

  12. Xie J, Murone M, Luoh S-M, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–2. https://doi.org/10.1038/34201.

    Article  CAS  PubMed  Google Scholar 

  13. Aszterbaum M, Rothman A, Fisher M, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol. 1998;110(6):885–8. https://doi.org/10.1046/j.1523-1747.1998.00222.x.

    Article  CAS  PubMed  Google Scholar 

  14. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 1998;280(5369):1603–7. http://www.ncbi.nlm.nih.gov/pubmed/9616123. Accessed 24 Dec 2017.

    Article  CAS  PubMed  Google Scholar 

  15. Keeler RF. Teratogenic compounds of veratrum californicum (Durand). X. Cyclopia in rabbits produced by cyclopamine. Teratology. 1970;3(2):175–80. https://doi.org/10.1002/tera.1420030210.

    Article  CAS  PubMed  Google Scholar 

  16. Incardona JP, Gaffield W, Kapur RP, Roelink H. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development. 1998;125(18):3553–62. http://www.ncbi.nlm.nih.gov/pubmed/9716521. Accessed 24 Dec 2017.

    CAS  PubMed  Google Scholar 

  17. Sanchez P, Ruiz i Altaba A. In vivo inhibition of endogenous brain tumors through systemic interference of hedgehog signaling in mice. Mech Dev. 2005;122(2):223–30. https://doi.org/10.1016/j.mod.2004.10.002.

    Article  CAS  PubMed  Google Scholar 

  18. Dirix L, Rutten A. Vismodegib: a promising drug in the treatment of basal cell carcinomas. Future Oncol. 2012;8(8):915–28. https://doi.org/10.2217/fon.12.82.

    Article  CAS  PubMed  Google Scholar 

  19. Proctor AE, Thompson LA, O’Bryant CL. Vismodegib. Ann Pharmacother. 2014;48(1):99–106. https://doi.org/10.1177/1060028013506696.

    Article  CAS  PubMed  Google Scholar 

  20. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor Vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502–11. https://doi.org/10.1158/1078-0432.CCR-10-2745.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res. 2011;17(8):2512–20. https://doi.org/10.1158/1078-0432.CCR-10-2736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Giannetti AM, Wong H, Dijkgraaf GJP, et al. Identification, characterization, and implications of species-dependent plasma protein binding for the oral hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem. 2011;54(8):2592–601. https://doi.org/10.1021/jm1008924.

    Article  CAS  PubMed  Google Scholar 

  23. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9. https://doi.org/10.1056/NEJMoa1113713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021–6.e8. https://doi.org/10.1016/j.jaad.2015.03.021.

    Article  PubMed  Google Scholar 

  25. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. https://doi.org/10.1186/s12885-017-3286-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Erivedge. Package insert. San Francisco: Genentech, Inc; 2012.

    Google Scholar 

  27. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51–70. https://doi.org/10.1126/scitranslmed.3001599.

    Article  CAS  Google Scholar 

  28. Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–9. https://doi.org/10.1158/1078-0432.CCR-13-1710.

    Article  CAS  PubMed  Google Scholar 

  29. Goel V, Hurh E, Stein A, et al. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(4):745–55. https://doi.org/10.1007/s00280-016-2982-1.

    Article  CAS  PubMed  Google Scholar 

  30. Zollinger M, Lozac’h F, Hurh E, Emotte C, Bauly H, Swart P. Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(1):63–75. https://doi.org/10.1007/s00280-014-2468-y.

    Article  CAS  PubMed  Google Scholar 

  31. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

    Article  CAS  PubMed  Google Scholar 

  32. Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016;75(1):113–125.e5. https://doi.org/10.1016/j.jaad.2016.02.1226.

    Article  CAS  PubMed  Google Scholar 

  33. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatology Venereol. 2017;32:372. https://doi.org/10.1111/jdv.14542.

    Article  CAS  Google Scholar 

  34. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8):1735–44. https://doi.org/10.1038/jid.2011.48.

    Article  CAS  PubMed  Google Scholar 

  35. Odomzo. Package insert. Mumbai: Sun Pharmceutical Industries Ltd; 2015.

    Google Scholar 

  36. Sharpe HJ, Pau G, Dijkgraaf GJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327–41. https://doi.org/10.1016/j.ccell.2015.02.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Brinkhuizen T, Reinders MG, van Geel M, et al. Acquired resistance to the hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):1005–8. https://doi.org/10.1016/j.jaad.2014.08.001.

    Article  CAS  PubMed  Google Scholar 

  38. Chang ALS, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–5. https://doi.org/10.1001/archdermatol.2012.2354.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wolfe CM, Green WH, Cognetta AB, Hatfield HK. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg. 2012;38(11):1863–6. https://doi.org/10.1111/j.1524-4725.2012.02513.x.

    Article  CAS  PubMed  Google Scholar 

  40. Danial C, Sarin KY, Oro AE, Chang ALS. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res. 2016;22(6):1325–9. https://doi.org/10.1158/1078-0432.CCR-15-1588.

    Article  CAS  PubMed  Google Scholar 

  41. Wang C, Wu H, Evron T, et al. Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs. Nat Commun. 2014;5:4355. https://doi.org/10.1038/ncomms5355.

    Article  CAS  PubMed  Google Scholar 

  42. Chen L, Aria AB, Silapunt S, Lee H-H, Migden MR. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2017:fon-2017-0457.;14:515. https://doi.org/10.2217/fon-2017-0457.

    Article  CAS  PubMed  Google Scholar 

  43. Wang C, Wu H, Katritch V, et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature. 2013;497(7449):338–43. https://doi.org/10.1038/nature12167.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ransohoff KJ, Tang JY, Sarin KY. Squamous change in basal-cell carcinoma with drug resistance. N Engl J Med. 2015;373(11):1079–82. https://doi.org/10.1056/NEJMc1504261.

    Article  CAS  PubMed  Google Scholar 

  45. Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang ALS. Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma. JAMA Dermatol. 2016;152(5):527–32. https://doi.org/10.1001/jamadermatol.2015.4330.

    Article  PubMed  Google Scholar 

  46. Eisemann N, Waldmann A, Geller AC, et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol. 2014;134(1):43–50. https://doi.org/10.1038/jid.2013.304.

    Article  CAS  PubMed  Google Scholar 

  47. Bhutani T, Abrouk M, Sima CS, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017;77(4):713–8. https://doi.org/10.1016/j.jaad.2017.03.038.

    Article  CAS  PubMed  Google Scholar 

  48. Lacouture ME, Dréno B, Ascierto PA, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218–29. https://doi.org/10.1634/theoncologist.2016-0186.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Ally MS, Tang JY, Lindgren J, et al. Effect of calcium channel blockade on vismodegib-induced muscle cramps. JAMA Dermatol. 2015;151(10):1132–4. https://doi.org/10.1001/jamadermatol.2015.1937.

    Article  PubMed  Google Scholar 

  50. Chang A. Levocarnitine in treating patients with vismodegib-associated muscle spasms. https://clinicaltrials.gov/ct2/show/NCT01893892.

  51. Dummer R, Basset-Seguin N, Hansson J, et al. Impact of treatment breaks on vismodegib patient outcomes: exploratory analysis of the STEVIE study. J Clin Oncol. 2015;33(15_suppl):9024. https://doi.org/10.1200/jco.2015.33.15_suppl.9024.

    Article  Google Scholar 

  52. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221–36; quiz 237–8. https://doi.org/10.1016/j.jaad.2014.07.033.

    Article  CAS  PubMed  Google Scholar 

  53. Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1720–31. https://doi.org/10.1016/S1470-2045(16)30566-6.

    Article  CAS  PubMed  Google Scholar 

  54. Sofen H, Gross KG, Goldberg LH, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015;73(1):99–105.e1. https://doi.org/10.1016/j.jaad.2015.03.013.

    Article  CAS  PubMed  Google Scholar 

  55. Alcalay J, Tauber G, Fenig E, Hodak E. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. J Drugs Dermatol. 2015;14(3):219–23. http://www.ncbi.nlm.nih.gov/pubmed/25738842. Accessed 27 Jan 2018.

    PubMed  Google Scholar 

  56. Chang ALS, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. JAMA Dermatol. 2013;149(5):639–41. https://doi.org/10.1001/jamadermatol.2013.30.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Kahana A, Worden FP, Elner VM. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131(10):1364–6. https://doi.org/10.1001/jamaophthalmol.2013.4430.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388–99. https://doi.org/10.1016/j.ccr.2010.02.027.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745–51. https://doi.org/10.1200/JCO.2013.49.9525.

    Article  CAS  PubMed  Google Scholar 

  60. Jin G, Sivaraman A, Lee K. Development of taladegib as a sonic hedgehog signaling pathway inhibitor. Arch Pharm Res. 2017;40(12):1390–3. https://doi.org/10.1007/s12272-017-0987-x.

    Article  CAS  PubMed  Google Scholar 

  61. Binns W, James LF, Shupe JL. Toxicosis of veratrum californicum in ewes and its relationship to a congenital deformity in lambs. Ann N Y Acad Sci. 1964;111:571. https://doi.org/10.1111/j.1749-6632.1964.tb53124.x.

    Article  CAS  PubMed  Google Scholar 

  62. Chen L, Aria AB, Silapunt S, Lee H-H, Migden MR. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018;14(6):515–25. https://doi.org/10.2217/fon-2017-0457.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas MD Anderson Cancer Center, Department of Dermatology, Houston, TX, USA

    Leon Chen

  2. University of Texas McGovern Medical School at Houston, Department of Dermatology, Houston, TX, USA

    Sirunya Silapunt

  3. The University of Texas MD Anderson Cancer Center, Departments of Dermatology and Head and Neck Surgery, Mohs Surgery Center, Houston, TX, USA

    Michael R. Migden

Authors
  1. Leon Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sirunya Silapunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael R. Migden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael R. Migden .

Editor information

Editors and Affiliations

  1. The University of Texas MD Anderson Cancer Center, Departments of Dermatology and Head and Neck Surgery, Mohs Surgery Center, Houston, TX, USA

    Michael R. Migden

  2. The University of Texas MD Anderson Cancer Center, Department of Dermatology, Houston, TX, USA

    Leon Chen

  3. University of Texas McGovern Medical School at Houston, Department of Dermatology, Houston, TX, USA

    Sirunya Silapunt

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chen, L., Silapunt, S., Migden, M.R. (2020). Hedgehog Signaling Pathway Inhibitors for Basal Cell Carcinoma. In: Migden, M., Chen, L., Silapunt, S. (eds) Basal Cell Carcinoma. Springer, Cham. https://doi.org/10.1007/978-3-030-26887-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-26887-9_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-26886-2

  • Online ISBN: 978-3-030-26887-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation